Related references
Note: Only part of the references are listed.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
Seyoung Seo et al.
ONCOTARGET (2017)
Clinical significance of MET amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum (FP) combination chemotherapy.
Seyoung Seo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Nomograms in oncology: more than meets the eye
Vinod P. Balachandran et al.
LANCET ONCOLOGY (2015)
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012
Kyu-Won Jung et al.
CANCER RESEARCH AND TREATMENT (2015)
Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer
In Rae Cho et al.
GASTRIC CANCER (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
H. S. Kim et al.
ANNALS OF ONCOLOGY (2013)
Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Hubert Piessevaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
Y. Y. Janjigian et al.
ANNALS OF ONCOLOGY (2012)
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
Akin Atmaca et al.
BMC CANCER (2012)
Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer
S. G. Hwang et al.
EJSO (2012)
Nomogram Predicting Long-Term Survival After D2 Gastrectomy for Gastric Cancer
Dong-Seok Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models
Dong Hoe Koo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Evaluation of response rate and disease control rate as potential predictors of overall survival in anthracycline-pretreated women receiving first-line chemotherapy for metastatic breast cancer (MBC).
J. Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
Jason S. Gold et al.
LANCET ONCOLOGY (2009)
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from southwest oncology group Randomized trials
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy
Jong Gwang Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer
Pooja R. Patel et al.
CANCER (2007)
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma
J. Lee et al.
ANNALS OF ONCOLOGY (2007)
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
Anna D. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data
I Chou et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma
MW Kattan et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
MW Kattan et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
